Inactive Instrument

Highlights Innovate Biopharmaceuticals Inc Nasdaq

Equities

US61174L5012

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

North American Morning Briefing : Tech in Focus on -2-	25/03	DJ
North American Morning Briefing : Investors Await Powell's Jackson Hole Speech	25/23/25	DJ
Illumina cuts annual profit forecast as biotech funding woes linger	10/23/10	RE
Illumina cuts annual profit forecast	10/23/10	RE
9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome	30/23/30	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
9 Meters Biopharma, Inc. Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity	05/23/05	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome	29/22/29	CI
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration with Gustave Roussy	14/22/14	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/22/08	CI
9 Meters Biopharma Launching 1-for-20 Reverse Stock Split; Shares Drop	17/22/17	MT
9 Meters Biopharma Reports Positive Final Results in Short Bowel Syndrome Trial; Shares Jumps After Hours	27/22/27	MT
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome	27/22/27	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/22/15	CI
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome	30/22/30	CI
9 Meters Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/22/16	CI
North American Morning Briefing : Tech Futures -2-	13/22/13	DJ
9 Meters Biopharma, Inc. Enters into an Exclusive License Agreement with EBRIS Srl	14/22/14	CI
9 Meters Biopharma Says Patent Application Allowed for NM-136 to Treat Certain Metabolic Disorders	13/22/13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Innovate Biopharmaceuticals Inc Nasdaq

Equities

US61174L5012

Highlights

Filters